Recombinant Human CD47 protein, His-tagged

• Cat.No.: CD47-7862H
• Product Overview: Recombinant Human CD47 protein(Q08722-1)(Gln19-Pro139), fused with C-terminal His tag, was expressed in HEK293.

Specification

• Species: Human
• Source: HEK293
• Tag: His
• Protein Length: Gln19-Pro139
• Tag: C-His
• Form: Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 5% trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Human CD47, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human SIRP alpha, hFc Tag with the EC50 of 82.1ng/ml determined by ELISA.
• Molecular Mass: The protein has a predicted MW of 14.5 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Tris-Bis PAGE result.
• Endotoxin: Less than 1EU per μg by the LAL method.
• Purity: > 95% as determined by Tris-Bis PAGE
• Storage: Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
• Reconstitution: Centrifuge tubes before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
• Publications:
  Co-coating of receptor-targeted drug nanocarriers with anti-phagocytic moieties enhances specific tissue uptake versus non-specific phagocytic clearance (2017)

Gene Information

• Gene Name: CD47 CD47 molecule [ Homo sapiens ]
• Official Symbol: CD47
• Synonyms: CD47; CD47 molecule; CD47 antigen (Rh related antigen, integrin associated signal transducer) , MER6; leukocyte surface antigen CD47; antigen identified by monoclonal 1D8; antigenic surface determinant protein OA3; CD47 glycoprotein; IAP; integrin associated protein; OA3; Rh related antigen; Rh-related antigen; integrin-associated protein; integrin-associated signal transducer; CD47 antigen (Rh-related antigen, integrin-associated signal transducer); MER6
• Gene ID: 961
• mRNA Refseq: NM_001777
• Protein Refseq: NP_001768
• MIM: 601028
• UniProt ID: Q08722

Case Study

Case 1: Tan Q, et al. J Cancer. 2025

Glioblastoma (GBM) is a tough brain tumor with a poor prognosis, mainly because it can grow and spread aggressively. The low oxygen levels in GBM help the tumor cells grow, spread, and resist treatment. This study highlights how proteins like HIF-1α and CD47 are overly active in GBM. High levels of these proteins are linked to shorter survival times for patients. It turns out, HIF-1α and CD47 seem to boost each other in GBM. Experiments showed that altering levels of HIF-1α and CD47 affected how fast the cancer cells could grow and spread, with HIF-1α controlling important pathways that help the tumor adapt and thrive.

Fig1. Western blot of CD47 protein expression in GBM.

Fig2. Western blot showing CD47 protein expression in GBM.

Case 2: Biedermann A, et al. Haematologica. 2024

Macrophages are vital in helping treatments like tafasitamab work against diffuse large B-cell lymphoma (DLBCL), but their effectiveness can be reduced by high CD47 and SIRPα levels on tumors and macrophages, respectively. This study found that blocking CD47 boosts tafasitamab's ability to kill cancer cells. High CD47 and SIRPα levels were observed in lymphoma, hindering macrophage function. Adding an anti-CD47 antibody improved results in lab tests and patient samples, even against low CD19 cells, and led to better outcomes in mouse models.

Fig1. The CRISPR/Cas9 system was used to alter gene expression in Toledo cells.

Fig2. Kaplan-Meier plot showing animal survival until a final tumor volume of 1,500 mm3 was reached.

Application

CD47 is a key player in the immune system, found on a variety of cells like tumor and immune cells. It teams up with the protein SIRPα to send out a “don’t eat me” message, helping cells dodge the immune system's watchful eye. Scientists often use recombinant CD47 in studies to get a better grip on how it helps cancer cells slip past immune detection, and to see if blocking this CD47-SIRPα chatter might boost the body's ability to fight tumors. In blood cancers like AML and MDS, too much CD47 generally means a bad prognosis, but mixing anti-CD47 antibodies with other treatments has been shown to up the anti-cancer ante. CD47 doesn’t just hang out with SIRPα; it also interacts with integrin αvβ3, kicking off a bunch of signals that help regulate how cells stick together and move around. Scientists use recombinant CD47 to dive into these interactions and learn more about its role in immune cell activity and communication. Its overexpression in cancers helps cancer cells escape immune attacks by binding to SIRPα on macrophages. Researchers believe that combining CD47 inhibitors with other cancer treatments like PD-1 blockers or chemotherapy could pack a bigger punch against tumors, and studies are happening to test these ideas out. Beyond research, recombinant CD47 plays a crucial role in industrial applications. It helps whip up specialized antibodies used in a bunch of lab techniques to spot CD47 in cells and tissues, handy for many scientific and diagnostic purposes. The protein is also a hot candidate in drug development, inspiring treatments like monoclonal antibodies aimed at CD47. Some of these are already in clinical trials, showing promise both in safety and their ability to help treat conditions. All in all, CD47 is a big deal in fields like cancer immunology and drug development, sparking loads of interest and new therapies.

Fig1. Overview of canonical versus noncanonical CD47 signaling. (Ruhi Polara, 2024)